Table 2 |
||
|
Disease-modifying anti-rheumatic drugs (DMARDs) used during the 10 years of follow-up |
||
| DMARD |
No (%) of patients |
Mean time (months) ± SD |
|
|
||
| Methotrexate |
86 (76.7%) |
63.0 ± 39.2 |
| Sulfasalazine |
58 (51.7%) |
44.7 ± 42.6 |
| Methotrexate + sulfasalazine |
33 (29.4%) |
37.7 ± 33.9 |
| Gold salts |
33 (29.4%) |
23.2 ± 24.0 |
| Hydroxychloroquine |
24 (21.4%) |
20.6 ± 17.5 |
| Leflunomide |
24 (21.4%) |
20.7 ± 18.2 |
| D-penicillamine |
2 (1.7%) |
23.4 ± 23.2 |
| Ciclosporin |
4 (3.5%) |
23.0 ± 23.3 |
| Etanercept |
12 (10.7%) |
16.7 ± 18.3 |
| Infliximab |
9 (8.0%) |
19.4 ± 7.0 |
| Adalimumab |
4 (3.5%) |
15.4 ± 18.7 |
| Anakinra |
1 (0.8%) |
8.9 |
| Abatacept |
1 (0.8%) |
2.1 |
|
|
||
|
Courvoisier et al. Arthritis Research & Therapy 2008 10:R106 doi:10.1186/ar2498 |
||
